Clinical Trial Update: Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating whether ACE inhibitors and ARBs can provide renal protection in primary hyperoxaluria was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria

Drugs mentioned

• ACE inhibitors
• Angiotensin II receptor blockers (ARBs) (Angiotensin II receptor blockers)

Snippet

Sponsor: Mayo Clinic | Conditions: Hyperoxaluria | Phase 3 | Status: WITHDRAWN